SML0654
恩他卡朋
≥98% (HPLC), COMT inhibitor, powder
别名:
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide
Product Name
恩他卡朋, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to light brown
溶解性
DMSO: 20 mg/mL, clear
储存温度
room temp
SMILES字符串
[N+](=O)([O-])c1c(c(cc(c1)\C=C(\C(=O)N(CC)CC)/C#N)O)O
InChI
1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChI key
JRURYQJSLYLRLN-BJMVGYQFSA-N
正在寻找类似产品? 访问 产品对比指南
应用
Entacapone has been used in high-performance bioaffinity chromatography.
生化/生理作用
Entacapone acts predominantly in the intestine. It increases the bioavailability of levodopa. Levodopa is known to be associated with many complications such as motor fluctuations. COMT inhibitors have been used to overcome these adverse effects of levodopa by reducing its metabolism. Entacapone exhibits its inhibition action on COMT in the peripheral nervous system.
Entacapone is a catechol-O-methyl transferase (COMT) inhibitor. Used in treatment of Parkinson′s disease, entacapone is administered with L-DOPA to inihibit COMT from converting L-DOPA into a compound that cannot cross the blood brain barrier.
Entacapone is a catechol-O-methyl transferase (COMT) inhibitor. Antiparkinson; anti-Dyskinesia.
特点和优势
This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Alice Petty et al.
Molecular imaging and biology, 25(6), 1054-1062 (2023-10-24)
There is robust evidence that people with schizophrenia show elevated dopamine (DA) synthesis capacity in the striatum. This finding comes from positron emission tomography (PET) studies using radiolabelled l-3,4-dihydroxyphenylalanine (18F-DOPA). DA synthesis capacity also appears to be elevated in the
Entacapone in the treatment of Parkinson's disease
Schrag Anette
Lancet Neurology, 4(6), 366-370 (2005)
Principles of Treatment in Parkinson's Disease, 133-133 (2005)
Fabrizio Stocchi et al.
Parkinsonism & related disorders, 20(12), 1335-1340 (2014-10-13)
IPX066, an investigational extended-release carbidopa-levodopa (CD-LD) preparation, has demonstrated a rapid attainment and prolonged maintenance of therapeutic LD plasma concentrations in advanced Parkinson's disease (PD). This phase-3 crossover study assessed its efficacy and safety vs. CD-LD plus entacapone (CL + E). At
Maximiliano Rapanelli et al.
Behavioural brain research, 280, 92-100 (2014-12-02)
Dopamine encodes reward and its prediction in reinforcement learning. Catechol-O-methyltransferase (COMT) activity in the medial prefrontal cortex (mPFC) has been shown to influence cognitive abilities by modifying dopamine clearance. Nevertheless, it is unknown how COMT in the mPFC influences operant
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持